Search Results

January 2022 "OXFORD, England--Professor Charlotte Deane, Ph.D., of the University of Oxford, has joined Professor Deane joins Exscientia’s technology leadership team, reporting to Chief Technology Officer, Professor Deane is one of the UK’s most accomplished bioinformaticians. Prior to this, Professor Deane was Deputy Executive Chair of the Engineering and Physical Sciences Research Professor Deane holds a B.A. in Chemistry from the University of Oxford and a Ph.D. in Biochemistry from

expanded to include chronic cough, in addition to the rights to develop certain retained compounds for Charcot-Marie-Tooth

This might not be a big deal for many, but in this new era of making sure that historically excluded October, here is my bucket list of the 3 things that people should absolutely experience: The Day of the Dead Mariachi song: I typically do not sing to these since they are dear to Mexican childhood memories, and

"Dear Sir or Madam, dear Colleagues, It gives me great pleasure to announce the fourth hybrid symposium

in Class B GPCRs, the membrane-driven modulation of mGluR2, and a big headline, Novo Nordisk’s $2.2B deal

For most researchers, that’s a dead end. For Alessandro Nicoli, it’s an opportunity.

Molecule"; Novo Nordisk looks to next generation of obesity, diabetes drugs with $550M Replicate research deal MC4R; Recursion completes Exscientia acquisition, signaling a fresh AI–GPCR chapter; OMass–Genentech deal

The realization that he could ask—and answer—complex biological questions with a computer sealed the deal

We have achieved a great deal in the last decade, such as the first-ever AI-designed drug candidates

November 2021 "Cambridge’s Japanese-owned life sciences company Sosei Heptares has clinched a lucrative deal

in VLGR1 have been associated with the human Usher syndrome (USH), the most common form of inherited deaf-blindness

Although they form an ancient signaling system, there is still a great deal of variety in neuropeptides

Development of Precision Medicine Platform Sosei Heptares and Neurocrine Biosciences won Top Out-Licensing Deal on the 8th annual Japan Deal of the Year Call for GPCR Papers GPCRs: Signal Transduction.

That leads to premature investment in weak scaffolds or endless tinkering with dead ends. This doesn’t mean an overnight overhaul. It means a commitment to continuous improvement — starting with the highest-friction gaps and working

Dear GPCR Enthusiasts , Get ready for an exciting learning experience with our newly updated Principles

This is the kind of insight that makes the difference between a dead-end program and a well-informed

Premium keeps you oriented and out of avoidable dead-ends. FAQ 🔹 What’s included?  

from ARPA-H’s Sprint for Women’s Health Nxera Pharma Wins Biotech Company of the Year and Financing Deal

Progress Parker Moss to Join Exscientia as EVP, Corporate Development Confo Therapeutics Nominated for 'Deal

Advanced Therapy Showcase in Tokyo, Japan, organized by LINK-J Jounce takes the cash under amended deal

sugar monophosphates; Pharmacology 2025; Nxera Pharma earns $10m milestone from AbbVie neurological deal

Dear GPCR Community, Before diving into this week's news, prepare for an incredible learning journey!

Dear GPCR Enthusiasts! Get ready to save the dates! Dr.

Septerna sells GPCR program to Vertex for $48 million Merck KGgA collaborates with Exscientia plc in deal

antagonists BenevolentAI, Exscientia on the comeback trail after securing separate AI drug discovery deals

Exclusive Deal for Scientists in Developing Nations If you reside and work in a developing country, complete

Exclusive Deal for Scientists Residing and Working in Developing Nations If you live and work  in a developing

For drug hunters working at the GPCR interface, the difference between a successful lead and a dead-end

Deak, A. K ´ onigstorfer, M. Mozhayeva, Y. Sara, T.C. Südhof, and ¨ E.T. Kavalali. 2001.

The right information at the right time can mean the difference between a breakthrough and a dead end